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ABSTRACT
Purpose: To improve stratiication of risk-adapted treatment for non-metastatic 
(M0), standard-risk medulloblastoma patients by prospective evaluation of biomarkers 
of reported biological or prognostic signiicance, alongside clinico-pathological 
variables, within the multi-center HIT-SIOP-PNET4 trial.
Methods: Formalin-ixed parafin-embedded tumor tissues were collected from 
338 M0 patients (>4.0 years at diagnosis) for pathology review and assessment 
of the WNT subgroup (MBWNT) and genomic copy-number defects (chromosome 17, 
MYC/MYCN, 9q22 (PTCH1) and DNA ploidy). Clinical characteristics were reviewed 
centrally.
Results: The favorable prognosis of MBWNT was conirmed, however better outcomes were observed for non-MBWNT tumors in this clinical risk-deined cohort compared to previous disease-wide clinical trials. Chromosome 17p/q 
defects were heterogeneous when assessed at the cellular copy-number level, 
and predicted poor prognosis when they occurred against a diploid (ch17(im)/
diploid(cen)), but not polyploid, genetic background. These factors, together with 
post-surgical tumor residuum (R+) and radiotherapy delay, were supported as 
independent prognostic markers in multivariate testing. Notably, MYC and MYCN 
ampliication were not associated with adverse outcome. In cross-validated survival 
models derived for the clinical standard-risk (M0/R0) disease group, (ch17(im)/
diploid(cen); 14% of patients) predicted high disease-risk, while the outcomes of 
patients without (ch17(im)/diploid(cen)) did not differ signiicantly from MBWNT, allowing re-classiication of 86% as favorable-risk.
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Conclusion: Biomarkers, established previously in disease-wide studies, behave 
differently in clinically-deined standard-risk disease. Distinct biomarkers are required 
to assess disease-risk in this group, and deine improved risk-stratiication models. 
Routine testing for speciic patterns of chromosome 17 imbalance at the cellular level, 
and MBWNT, provides a strong basis for incorporation into future trials.
INTRODUCTION
Medulloblastoma is the most common malignant 
brain tumor in children. Risk-adapted therapeutic protocols 
in non-infant patients encompass maximal surgical 
resection, cranio-spinal radiotherapy and chemotherapy. 
Treatment groups and intensity are deined by the presence 
(‘high-risk’ disease) or absence (‘standard-risk’) of clinical 
features associated with a poor prognosis; metastatic 
disease at diagnosis and/or signiicant post-operative tumor 
residues, and this stratiication currently forms the basis of 
patient selection into clinical trials [1].
Recent advances in the biological sub-classiication 
of medulloblastoma are leading to the conception 
of clinical trials aimed at more precise therapeutic 
stratiication and improved outcomes [1]. Historical 
studies have identiied biomarkers consistently associated 
with favorable (β-catenin nuclear immunopositivity as a 
marker of the WNT medulloblastoma molecular subgroup 
(MB
WNT
)) and poor (large-cell/anaplastic (LCA) pathology, 
MYC gene family ampliication) prognosis [2–9], and 
their retrospective evaluation in the SIOP-UKCCSG-
PNET3 clinical trial has validated their use alongside 
clinical factors for the improved deinition of disease risk-
stratiication groups in disease-wide studies of non-infant 
medulloblastoma [10]. These stratiication schemes will 
now form the basis of treatment selection in contemporary 
international clinical trials [1]. Additionally, further 
biomarkers with potential prognostic value, most notably 
the discovery of the four consensus medulloblastoma 
molecular subgroups (MB
WNT
, Sonic hedgehog (MBSHH), Group 3 (MBGroup3) and Group 4 (MBGroup4)), are emerging from recent research studies on retrospective cohorts of 
medulloblastoma patients [1, 11–14].
The validation of novel biomarkers and risk-
stratiication schemes in clinically-controlled cohorts is 
thus essential to their clinical application. Moreover, the 
speciic therapeutic regimens used may potentially impact 
the prognostic signiicance of speciic biomarkers, and 
validation of their relevance within the deined treatment 
groups used in current clinical trials (i.e. the clinical 
standard- or high-risk disease groups) is necessary. This will 
require large-scale and coordinated international studies.
Here, we report the irst European prospective study 
of medulloblastoma biomarkers, undertaken as part of the 
multi-center HIT-SIOP-PNET4 trial (2001–2006), which 
enrolled 338 children from 120 centres, with clinically-
deined non-metastatic, standard-risk medulloblastoma 
[15]. Suficient FFPE tumor material was collected for 
prospective assay (2004–2010) of a selected panel of 
biomarkers of previously reported biological or prognostic 
signiicance (i.e. in ≥2 published series). The study aimed 
to (i) improve the early identiication of the ~20% patients 
with standard-risk medulloblastoma which cannot be 
cured by current treatment concepts, and (ii) identify 
patients with a favorable prognosis who may qualify for a 
controlled reduction of adjuvant treatment schemes.
RESULTS
HIT-SIOP-PNET4: Clinical and  
treatment-related factors
338 patients, aged 4 to 21 at diagnosis, were 
enrolled and their clinical characteristics have been 
reported previously [15]. In summary, male patients 
predominated (211 male, 127 female) and the ive-year 
EFS (all patients, including R+ disease) was 79 ± 2%. 
Features signiicantly associated with reduced EFS 
in univariate analysis in the clinical study were: (i) R+ 
disease (31/317 (9.8%); p = 0.020), and (ii) a delay 
to the start of radiotherapy (≥49 days after surgery 
(30/335 (9.0%); p = 0.050) or as a continuous variable 
(p = 0.025)). Patient gender and age at diagnosis were not 
associated with EFS [15]. Histopathological review was 
completed for 336/338 patients, and identiied 273 CMB 
(81%), 47 DMB (14%) and 16 LCA (5%) tumors. There 
was no survival difference between CMB and DMB 
patients. The 16 patients with LCA subtype tumors 
enrolled on the study prior to amendment showed a higher 
frequency of relapses, but these did not reach signiicance 
[15]. The exclusion of further LCA patients, together with 
M+ patients, from the HIT-SIOP-PNET4 cohort, as well 
as sharpening of the deinitions of DMB and LCA in the 
revised WHO classiication of tumors of the CNS in 2007 
[16] may account for any variation in the distribution 
of histopathological variants compared to previously-
reported non-infant disease-wide trials (i.e. 71 CMB 
(61%), 22 DMB (19%) and 23 LCA (20%) in SJMB96 
[3]; 174 CMB (84%), 14 DMB (7%) and 19 LCA (9%) 
in SIOP-UKCCSG-PNET3 [10]). Data are summarized in 
Table 1.
MB
WNT
 subgroup
22.8% (58/254) of assessable tumors were MB
WNT
 
positive by β-catenin IHC [10] (Figure 1A). 15.9% of 
tumors (31/195) harbored CTNNB1 activating mutations 
Oncotarget3www.impactjournals.com/oncotarget
(Supplementary Figure 1); all except one were observed in 
tumors with strong nuclear protein accumulation (n = 30; 
p < 0.001; Figure 1B). A further 12 tumors displayed 
β-catenin positivity (28.6% (12/42)) in the absence of 
CTNNB1 exon 3 mutation.
MB
WNT
 subgroup tumors were clinically, 
pathologically and molecularly distinct [11]: All except 
one displayed CMB or LCA histology (p = 0.005), 
and the group displayed gender parity in contrast to the 
male predominance in non-MB
WNT
 patients (p = 0.002). 
All copy number aberrations (CNAs) tested were infrequent 
or absent in MB
WNT
 and polyploidy was less frequent (p = 
0.002; Figure 1B). MB
WNT
 patients showed a broader age 
distribution than non-MB
WNT
, with 11/58 (19.0%) MB
WNT
 
patients ≥16.0 years old at diagnosis, suggesting a secondary 
peak in adolescents/young adults (Figure 1B, 1C).
Favorable outcomes for patients with MB
WNT
 tumors 
were conirmed in univariate analysis, (Table 1, Figure 2 
(p = 0.019, Cox proportional hazards test; p = 0.003, log-
rank test)). CTNNB1 mutation did not reach signiicance 
Table 1: Clinical, pathological and molecular characteristics of the HIT-SIOP-PNET4 cohort 
(n = 338; all patients with available data are shown), and univariate (Cox proportional hazards) 
analysis of their prognostic associations.
Variable Categories n Five-year pEFS ±SE Univariate Hazard Ratio (± CI) p-value
+Gender
Male (M)
Female (F)
Ratio (M:F)
211
127
1.66:1
0.79 ± 0.03
0.80 ± 0.04
1.0
0.85 (0.52–1.41)
0.533
Age*
Median (years)
Min.-Max.
9.0
3–20 − 0.99 (0.93–1.05) 0.754
+Pathology**
All others
LCA
320
16
0.80 ± 0.02
0.64 ± 0.14
1.0
1.76 (0.71–4.37) 0.262
+Residual tumor
≤1.5 cm2
>1.5 cm2
286
31
0.82 ± 0.02
0.64 ± 0.09
1.0
2.34 (1.22–4.50) 0.020
+Time from diagnosis 
to radiotherapy
<49 days
≥49 days
305
30
0.81 ± 0.02
0.67 ± 0.09
1.0
1.93 (0.99–3.79) 0.050
Time from diagnosis 
to radiotherapy*
Median (days)
Min.-Max.
35
15–92 − 1.03 (1.00–1.05) 0.025
β-catenin nuclear 
accumulation
No
Yes
196
58
0.75 ± 0.03
0.91 ± 0.04
1.0
0.40 (0.17–0.94) 0.019
CTNNB1 mutation
No
Yes
164
31
0.75 ± 0.04
0.89 ± 0.06
1.0
0.37 (0.12–1.21) 0.058
MYC/MYCN 
ampliication (PCR)
No
Yes
160
23
0.79 ± 0.03
0.72 ± 0.09
1.0
1.26 (0.53–3.00) 0.606
MYC ampliication 
(iFISH)
No
Yes
157
4
0.81 ± 0.03
1.00
1.0
0.22 (0.02–29.16) 0.542
MYCN ampliication 
(iFISH)
No
Yes
147
13
0.82 ± 0.03
0.77 ± 0.12
1.0
1.41 (0.42–4.67) 0.588
17p loss and/or 17q 
gain (diploid(cen)) 
(iFISH)
No
Yes
127
24
0.85 ± 0.03
0.57 ± 0.10
1.0
3.12 (1.44–6.76) 0.007
Polyploid
No
Yes
72
85
0.78 ± 0.05
0.83 ± 0.04
1.0
0.81 (0.39–1.68) 0.572
PTCH1 (9q22) loss
No
Yes
138
13
0.80 ± 0.03
0.85 ± 0.10
1.0
0.82 (0.19–3.46) 0.781
*Assessed as a continuous variable.
**Patients with LCA tumors recruited prior to study amendment in November 2003. pEFS, event-free survival probability; 
SE, standard error; CI, 95% conidence interval. Signiicant prognostic associations are marked in bold type.
+Previously reported data shown for information [15].
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(Table 1, Figure 2A, 2B). 6/58 (10.3%) MB
WNT
 tumors 
relapsed; all had β-catenin nuclear accumulation in >50% 
of cells and 3/4 assessed tumors harbored a CTNNB1 
mutation (Supplementary Figure 2A). Of note, the EFS 
rate in MB
WNT
 patients aged ≥16.0 years at diagnosis 
appeared lower than in MB
WNT
 patients <16.0 years 
(p = 0.058; Figure 1D). Direct comparison of patients aged 
below 16.0 years from the HIT-SIOP-PNET4 and SIOP-
UKCCSG-PNET3 trials showed equivalent ive-year 
survival rates (±SE) for MB
WNT
 patients (0.951 (±0.034) 
vs. 0.877 (±0.058); p = 0.434), but signiicantly better 
outcomes (0.754 (±0.034) vs. 0.671 (±0.036); p = 0.033) 
in non-MB
WNT
 patients, and reduced frequencies of clinical 
high-risk features (M+ and/or R+ disease), in the HIT-
SIOP-PNET4 cohort (Supplementary Figure 3).
Copy number aberrations
MYC (2.5% (4/161) tumors tested) and MYCN 
(8.1% (13/160)) ampliications detected by iFISH were 
mutually exclusive and were detected in non-MB
WNT
 
disease (Figure 1). Neither was associated with previously 
reported high-risk clinical (residual tumor) or pathological 
(LCA tumors included in this study) [1] disease features, 
or an adverse prognosis (Table 1, Figure 2D, 2E). iFISH 
and qPCR estimations of MYC/MYCN copy number were 
concordant in 90% of tumors analyzed by both methods 
(n = 131). Polyploidy (54% (85/157)) and PTCH1 
(9q22) losses (10.6% (13/151)) were not associated with 
prognosis (Table 1, Figure 2C, 2G).
Chromosome 17 imbalances (q-arm gains and/
or p-arm losses) were frequent (45.7% (69/151) tumors 
assessed). Imbalances were molecularly heterogeneous 
(Figure 3), and occurred against diploid (2 signals) and 
polyploid (>2 signals) centromeric reference backgrounds 
(Figure 3A, 3C). Strikingly, this heterogeneity was 
clinically signiicant. Tumors with chromosome 
17 imbalances/diploid background (ch17(im)/diploid(cen); 
16% (24/151)) were signiicantly associated with a poor 
outcome (p < 0.007; Table 1, Figure 2F), while tumors 
with imbalances/polyploid background (ch17(im)/
polyploid(cen); 30% (45/151)) were not, and behaved 
equivalently to balanced tumors (Figure 3B). Ch17(im)/
diploid(cen) (n = 24) most commonly involved p-arm loss 
Figure 1: MB
WNT
 subgroup tumors: clinical, pathological and molecular correlates. A. Examples of tumors scored negative 
and positive for β-catenin nuclear accumulation, with CTNNB1 status also indicated. B. Distribution of clinical, histopathological and 
molecular markers between the MB
WNT
 (nuclear β-catenin accumulation) and non-MB
WNT
 medulloblastoma subgroups. C. Age distributions 
of MB
WNT
 and non-MB
WNT
 patients. D. Kaplan-Meier plots and associated ‘p’ values (log-rank test) shown for MB
WNT
 patients with age at 
diagnosis younger than 16 years, older than 16 years versus non-MB
WNT
 cases.
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(to a single copy) in conjunction with q-arm gain (17/24), 
consistent with isochromosome (17q), but isolated p-arm 
losses (4/24) and q-arm gains (3/24) also contributed. This 
tumor group peaked in children 6–10 years at diagnosis 
and all but one tumor was found in non-MB
WNT
 disease, 
but the group was not associated with other clinico-
pathological factors (Figure 3D). Notably, the prognostic 
signiicance of ch17(im)/diploid(cen) was gender-speciic 
and 8/9 relapses in this group occurred in male patients 
(Supplementary Figure 4).
Clinical and biological prognostic factors: 
Multivariate analysis
Multivariate analyses were performed separately 
on the clinically-deined non-metastatic (i.e. M0) and 
standard-risk (i.e. M0/R0) patient cohorts within the 
HIT-SIOP-PNET4 study; these analyses were based on 
all features showing signiicance in univariate analysis 
(p < 0.05; Table 1, Figure 2). To account for all features 
not having been assessed in all patients, we performed this 
multivariate analysis on different patient groups, based on 
the data available (Table 2). In the non-metastatic patient 
cohort, R+ disease was independently signiicant in all 
analyses, while MB
WNT
 and time to radiotherapy were 
either signiicant or marginally signiicant, consistent with 
indings from the univariate analysis. In the standard-risk 
cohort (i.e. following removal of R+ patients), ch17(im)/
diploid(cen) was the only feature independently and 
signiicantly predictive of a poor outcome (Table 2).
Risk stratiication models for standard-risk 
medulloblastoma
The standard-risk patient group, deined by M0/R0 
disease, forms the basis of current clinical trials [1]. We 
therefore next used our data to develop risk-stratiication 
models for this patient group. First, we generated Cox 
models from all variables (listed in Table 1) using 90% 
of patients in our cohort, and selected the most signiicant 
Figure 2: Prognostic signiicance of molecular disease features in the HIT-SIOP-PNET4 cohort. Kaplan-Meier plots and 
associated ‘p’ values (log-rank test) are shown for each feature. Chromosome 17 losses and gains observed against a diploid centromeric 
reference score (diploid(cen)) are represented.
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model to predict survival for the remaining 10% of 
patients, using a 10-fold cohort re-selection strategy for 
cross-validation. Ch17(im)/diploid(cen) was selected as 
the sole prognostic feature in every fold, thus forming 
a model for the prediction of poor outcome within the 
standard-risk disease group (61 ± 13% vs. 89 ± 3% 
survival at ive-years, p = 0.009) (Figure 4). In each fold, 
the model was not improved by the addition of any other 
covariate. We next compared model performance in our 
standard-risk cohort, against the current clinico-biological 
stratiication scheme for the SIOP-PNET5 trial [1], which 
was deined previously based on disease-wide non-infant 
cohorts [1, 10, 14] (Figure 4a). Survival prediction at 
5-years using the new cross-validated model improved 
performance and increased the area-under-curve (AUC) 
from 0.609 to 0.630 in ROC curve analysis (Figure 4d), 
and allowed 86% (102/118) of patients to be classiied into 
a favorable-risk group, compared to 20% (24/118) in the 
established model. In view of the established favorable 
prognosis of MB
WNT
 tumors [1, 3, 10], conirmed in our 
cohort, we assessed the impact of MB
WNT
 status within 
this new model (Figure 4c). Inclusion was not detrimental 
to model performance (Figure 4d), however ive-year 
survival for the favorable-risk MB
WNT
 (96 ± 4%) and 
non-MB
WNT
 ch17(im)/diploid(cen) negative (87 ± 4%) 
patient groups were not signiicantly different (p = 0.189). 
Finally, indings were equivalent when patients aged up 
to 16.0 years at diagnosis were considered in isolation 
(Supplementary Figure 5).
DISCUSSION
The prospective assessment within HIT-SIOP-
PNET4 of disease-relevant biomarkers, with reported 
signiicance in ≥2 previous retrospective series, alongside 
clinical and pathological factors, has provided important 
new insights to biomarker-driven risk stratiication 
in clinically-deined standard-risk medulloblastomas. 
Post-operative residual tumor, delayed radiotherapy 
and MB
WNT
 were validated as independent prognostic 
factors. Importantly, in the standard-risk (M0/R0) disease 
group, which forms the basis of current clinical trials [1], 
the use of distinct biomarkers (chromosome 17 status 
determined at the cellular copy-number level) and novel 
survival models allows the improved stratiication 
Figure 3: Chromosome 17 defects in HIT-SIOP-PNET4 cohort tumors. Patterns (A, C) and prognostic signiicance (B.; ‘p’, 
log-rank tests) of chromosome 17 defects detected by iFISH. C. iFISH analysis showing (i) 17p loss (single green signals) and (ii) 17q 
gain (three green signals) against a diploid centromeric background (two red signals). Nuclei are counterstained blue. D. Relationship of 
ch17(im)/diploid(cen) defects to clinico-pathological and molecular disease features assessed (‘p’, Fisher’s exact or χ2 tests; corrected and 
uncorrected values are shown). Abbreviations: ch, chromosome; im, imbalance (p-gain and/or q-loss); diploid(cen), diploid centromeric 
signal; polyploidy(cen), polyploidy centromeric signal.
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Table 2: Multivariate analysis of independent risk factors in the HIT-SIOP-PNET4 cohort, shown for patients within the clinically-
deined non-metastatic (M0, R+/R0) disease and standard-risk (M0, R0) patient groups
Non-metastatic (M0, R+/R0) disease
Variable Category
Cohort 1 (n = 315)
Data available: Residual tumor status, 
Time to radiotherapy
Cohort 2 (n = 238)
Data available: Residual tumor status, 
Time to radiotherapy, β-catenin status
Cohort 3 (n = 136)
All data available
n HR (± CI) p n HR (± CI) p n HR (± CI) p
Residual tumor
≤1.5 cm2
>1.5 cm2
284 (90%)
31 (10%)
1.0
2.74 (1.41–5.34)
0.003
214 (90%)
24 (10%)
1.0
3.08 (1.47–6.48)
0.003
120 (88%)
16 (12%)
1.0
3.14 (1.17–8.45)
0.023
Time to 
radiotherapy
Continuous 315 1.03 (1.01–1.06) 0.004 238 1.04 (1.01–1.07) 0.022 136 1.04 (1.00–1.09) 0.076
β-catenin nuclear 
accumulation
No
Yes
Data not available 182 (76%)56 (24%)
1.0
0.37 (0.16–0.88)
0.025
104 (76%)
32 (24%)
1.0
0.25 (0.06–1.12) 0.070
17p loss and/
or 17q gain 
(diploid(cen))
No
Yes
Data not available Data not available 115 (85%)21 (15%)
1.0
1.95 (0.79–4.83) 0.149
Standard-risk (M0, R0) disease
Variable Category
Cohort 1 (n = 214) 
Data available: Time to radiotherapy, β-catenin 
status
Cohort 2 (n = 120) 
All data available
n HR (± CI) p n HR (± CI) p
Time to radiotherapy Continuous 214 1.01.03 (0.99–1.07) 0.111 120 1.03 (0.97–1.08) 0.339
β-catenin nuclear 
accumulation
No
Yes
165 (77%)
49 (23%)
1.0
0.45 (0.17–1.15) 0.096
93 (78%)
27 (22%)
1.0
0.22 (0.03–1.69) 0.145
17p loss and/or 17q gain 
(diploid(cen))
No
Yes
Data not available 103 (86%)17 (14%)
1.0
3.66 (1.40–9.52)
0.008
Patients with central radiological and pathological review were analyzed (n = 315). Variables which displayed statistical signiicance in 
univariate analysis (Table 1) were tested in separate multivariate analyses based on patients with available data. Statistically signiicant 
independent risk-factors and associated hazard ratios are marked in bold type. HR, hazard ratio; CI, 95% conidence interval.
Oncotarget8www.impactjournals.com/oncotarget
of disease-risk. Moreover, we have established irst 
mechanisms for prospective pan-European biological 
studies as a basis for the assessment of biomarker-driven 
therapies, and future therapeutic advances.
Assessment of MB
WNT
 subgroup patients in the 
HIT-SIOP-PNET4 cohort revealed signiicant new 
insights to their clinical behavior, and comparison to 
other trials-based studies, to support future trial design. 
Their favorable prognosis was validated, supporting their 
consideration for individualized risk-stratiied therapies; 
notably, despite equivalent EFS rates in the MB
WNT
 
groups, a signiicantly higher EFS was observed for 
the non-MB
WNT
 group in our non-metastatic HIT-SIOP-
PNET4 cohort (75% ive-year EFS) compared to previous 
studies of the SIOP-UKCCSG-PNET3 trials cohort which 
included high-risk patients [2, 3]. MB
WNT
 relapses were 
observed at higher frequency in patients with delayed 
radiotherapy or aged >16.0 years at diagnosis (Figure 1D; 
Supplementary Figure 2). Patients >16.0 years were not 
ascertained in our previous analyses of SIOP-UKCCSG-
PNET3 which deined the favorable prognosis of the 
MB
WNT
 group [2, 10], and the present data are consistent 
with the bi-modal age distribution and worse prognosis 
reported for adults compared to children within MB
WNT
 
in retrospective series [4, 17, 18]. Although the incidence 
of such cases is too low to draw irm conclusions, these 
observations thus indicate patient age >16.0 years and 
delayed radiotherapy negatively inluence survival in 
MB
WNT
, and indicate radiotherapy is important component 
of its multi-modal treatment. Similarly, only 1 event was 
observed in MB
WNT
 tumors also displaying previously 
reported high-risk disease features (MB
WNT
/R+ (n = 7), 
MB
WNT
/LCA (n = 5)) supporting their favorable prognosis 
following standard-risk therapy. CTNNB1 mutation 
Figure 4: Biomarker-driven risk-stratiication models for standard-risk (M0/R0) medulloblastoma based on patients 
from the HIT-SIOP-PNET4 cohort with data available for all parameters (n = 118). A. Established disease-wide survival 
model for non-infant medulloblastoma [1, 10, 14] (LCA pathology and/or MYC/MYCN ampliied, high-risk; MB
WNT
 and no high-risk 
features, favorable-risk; others, intermediate-risk). B. Empirically-derived survival model for non-infant, standard-risk medulloblastoma. 
C. Illustrative survival model for non-infant, standard-risk medulloblastoma, incorporating the distinction of MB
WNT
 patients into the 
empirically-derived model. Kaplan-Meier plots and associated ‘p’ values (log-rank tests) show EFS. M0, non-metastatic; R0, no signiicant 
post-surgical tumor residuum; ch17(im), ch17(im)/diploid(cen) tumors. D. Time-dependent receiver operator characteristic (ROC) curves 
showing predictive performance of the three models for survival at ive-years, determined as the area-under-curve (AUC). TP, true positive; 
FP, false positive. Chromosome 9 defects were not assessed in survival modelling due to missing data points.
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rates in MB
WNT
 tumors, deined by β-catenin IHC, were 
equivalent to SIOP-UKCCSG-PNET3 (30/42 (71.4%) 
and 20/31 (64.5%), respectively [10]) and our data did 
not support reduced survival rates in mutation-negative 
MB
WNT
 (Supplementary Figure 2A).
Study design, and the prospective collection of 
clinical material and biological data, was undertaken 
in 2000–2010. This limited our ability to assess in the 
PNET4 cohort the other non-MB
WNT
 molecular subgroups, 
on which consensus emerged in 2012 [11]. Insuficient 
FFPE-derived tumor material remained following our 
planned prospective analysis (see Materials and Methods; 
typically <200 ng double-stranded (ds)DNA [measured 
by picogreen luorometric quantitation] and ≤1 4 μm 
section remaining), to enable subgroup assessment using 
established methods (approximately 1 μg FFPE-extracted 
dsDNA required for DNA methylation array analysis [14, 
19, 20]; >2 sections for IHC-based assignment to MBSHH subgroup [21]).
From our indings, high-risk biomarkers previously 
validated in disease-wide studies appear to have different 
prognostic relevance in the standard-risk clinical disease 
group, from which tumors with high-risk clinical 
features (e.g. M+ disease) have been excluded. In this 
clinical context, MYC/MYCN ampliication and LCA 
were not associated with each other, with clinical high-
risk factors (one MYCN/R+ and one MYCN/LCA tumor 
were observed) or with poor prognosis when observed 
in isolation as risk-factors in the clinically-deined 
non-metastatic/standard-risk group reported. These 
indings are consistent with observations based on SIOP-
UKCCSG-PNET3 (which included high-risk patients), 
where MYC/MYCN ampliication were associated with 
LCA pathology and were prognostic in high-risk (i.e. 
when observed in tumors from patients with other high-
risk disease features) but not standard-risk disease [7, 10]. 
In most recent genomics studies, MYC-ampliied tumors 
were most commonly observed in MBGroup3, while MYCN-ampliied tumors were associated with MBSHH (where 
they were also associated with TP53 mutation and LCA) 
and MBGroup4, but were only prognostic in MBSHH [12, 14, 22–24]. Our indings may thus relect (i) the numbers of 
MYC/MYCN ampliied tumors observed in this cohort, or 
(ii) biological heterogeneity and/or subgroup-dependency, 
including the trial amendment to cease recruitment of 
patients with LCA tumors (see methods), potentially 
limiting ascertainment of tumors with interactions between 
these factors. Evaluation/outcome monitoring of further 
patients deined by these features will now be required, 
prior to any reinements of their prognostic relevance used 
in the design of future clinical studies.
Our indings fully support the continued 
consideration of R+ patients as high-risk, and their 
exclusion from the standard-risk disease group [1]. 
Most notably, ch17(im)/diploid(cen) was the strongest 
independent biomarker risk-factor in M0/R0 standard-risk 
disease, characterizing a patient group with <60% ive-year 
EFS; however, imbalances against a polyploid background 
were not signiicant. This previously undisclosed and 
clinically-signiicant heterogeneity observed between 
chromosome 17 imbalanced tumors is important, and these 
data suggest the biological impact of different patterns of 
chromosome 17 imbalance is equivalently heterogeneous. 
Variable prognostic associations have been reported for 
chromosome 17 imbalances in previous large studies 
[6, 10]; however, the complex patterns of imbalance 
revealed by iFISH analysis of individual tumor cells in 
this study were either not investigated or not detectable 
using the whole-biopsy copy number methodologies 
(e.g. array-CGH, SNP array) employed in many previous 
studies [9, 24–28]. Chromosome 17 imbalances are 
predominantly observed in MBGroup3 and MBGroup4 [24] and, in whole-biopsy SNP-array based investigations, Shih 
et al. [12] recently reported that the association between 
iso (17q) and a poor prognosis was restricted to MBGroup3 
patients. Concerted studies are now required to reconcile 
these indings and establish the relationship between tumor 
subgroup, cellular patterns of chromosome 17 imbalance, 
and prognosis.
Following designation of ch17 (im)/diploid (cen) 
tumors as high-risk in cross-validated survival models of 
standard-risk patients within the HIT-SIOP-PNET4 cohort, 
the EFS of remaining patients did not differ signiicantly 
from the MB
WNT
 group, allowing the classiication of 
>80% of patients into a favorable-risk category. This 
model outperforms established prognostication schemes 
in our standard-risk cohort.
Alongside methods developed for testing chromosome 
17 imbalances at the cellular level in routinely-collected 
tumor material, these indings provide a straightforward 
scheme for risk-stratiication in the clinically homogeneous 
group of children with standard-risk medulloblastoma, and 
a strong basis for their validation and further investigation 
in future clinical trials of this group. Future study concepts 
must ensure collection of suficient FFPE alongside high-
quality biological material (e.g. snap-frozen, histologically-
controlled tumor tissue), from large patient numbers, 
to support further biomarker discovery and validation, 
including understanding their behavior in the context of the 
consensus medulloblastoma expression / DNA methylation 
subgroups.
MATERIALS AND METHODS
Patient cohort, pathological review, material 
collection & processing
338 patients with non-metastatic (M0 [29]) 
medulloblastoma, treated in 120 European centers and 
11 countries, were enrolled on HIT-SIOP-PNET4 over a 
6 year period (2001–2006) [15]. Patients were randomized 
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to receive post-operative treatment with either hyper-
fractionated (HFRT) or conventionally fractionated/
standard (STRT) radiotherapy and were followed up 
for a median of 4.8 years; all patients received the same 
chemotherapy. Clinical features of the cohort have been 
reported [15] (summarized in Table 1). The two treatment 
arms showed no signiicant difference in 5-year event-
free survival (EFS) [15], and were considered together for 
biological analysis.
Post-operative radiological review was undertaken 
for 317/338 (93.7%) patients, the remainder were 
reviewed locally. Patients without signiicant post-surgical 
tumor residuum (≤1.5 cm2; R0) were deined as standard-
risk [1]. A histopathological diagnosis of medulloblastoma 
was conirmed by ive neuropathologists (including DF-B 
and TP), who performed central reference review of all 
patients. Tumors were classiied using WHO criteria 
[30], and assigned to the classic (CMB), desmoplastic/
nodular (DMB) or large-cell/anaplastic (LCA) sub-entities 
[16]. LCA were deined by a predominant component of 
tumor cells with either characteristic large-cell or severe 
anaplastic cytology, or both [8, 16, 31, 32]. DMB showed 
a signiicant tumor component with reticulin iber-free 
islands (nodules) surrounded by reticulin iber-rich 
tumor areas. Reactive iber induction (‘desmoplastic 
reaction’, e.g. due to leptomeningeal growth) did not 
qualify as DMB [16, 33]. A study amendment was made 
in November 2003 to not enroll further LCA tumors, on 
the basis of their reported poor prognosis [8, 15, 31, 32].
During sample processing for reference pathology, 
excess tumor material was collected for biological studies 
where available. Two slides (4 μm tissue sections) were 
prepared for β-catenin immunohistochemistry (IHC). 
In addition, two tubes with 4 × 20 μm sections were 
collected, one to isolate nuclei for interphase luorescence 
in situ hybridization (iFISH) analysis, the other for 
genomic DNA extraction (CTNNB1 mutation, MYC/
MYCN qPCR analysis (see below)). DNA was extracted 
using the QIAamp DNA Mini Tissue Kit (Qiagen GmbH, 
Düsseldorf, Germany) according to the manufacturer’s 
instructions.
Assessment of copy number aberrations
Tumor nuclei were isolated and CNAs of reported 
biological or prognostic signiicance assessed by iFISH 
using probes speciic for MYCN (2p24) and MYC (8q24) 
(ampliication previously associated with poor prognosis 
and LCA pathology [5–7, 10, 21]), PTCH1 (9q22; loss 
associated with the sonic hedgehog medulloblastoma 
molecular subgroup (MBSHH) and DMB [5, 6, 11, 17, 21]), and the p- and q- arms of chromosome 17 (imbalances 
associated with a poor prognosis [5, 6]), alongside 
reference probes to the chromosome 2, 8, 9 and 17 
centromeric regions, as previously described [5, 10]. 
Signals in >200 non-overlapping nuclei were scored 
to give region of interest: centromere signal ratios for 
individual cells. For chromosome gains and losses, the 
modal score was considered representative of genetic 
status. MYC or MYCN gene ampliication was deined 
by double-minute patterns or homogeneously staining 
regions in ≥5% of nuclei [5, 7, 10]. Tumor ploidy was 
determined as the modal status of the four centromeric 
probes (>2 signals at ≥2 probes, polyploid) assessed. 
Quantitative PCR (qPCR) was used to estimate MYC and 
MYCN gene copy numbers, as described [34, 35].
MB
WNT
 subgroup status
Assessment of β-catenin nuclear accumulation by 
IHC has been widely studied as an MB
WNT
 biomarker 
[9, 14, 36–38], and was performed as described using 
the monoclonal anti-β-catenin antibody 14 (Transduction 
laboratories) [2, 10, 39]. Tumors with >10% positive 
nuclei were scored positive (nuclear accumulation); the 
same cut-off as used in the published SIOP-UKCCSG-
PNET3 cohort [10]. The few tumors showing nuclear 
accumulation in single cells (typically <5%) were 
classiied negative. For CTNNB1 mutation analysis, 
exon 3 was PCR-ampliied from tumor DNA using the 
primers 5′-GATTTGATGGAGTTGGACATGG-3′/5′-
TGTTCTTGAGTGAAGGACTGAG-3′, and sequenced 
using standard methods [39].
Prospective biological studies: molecular 
biomarker assessment
Overall, biological data were collected prospectively 
from FFPE tumor material for 269/338 (79.5%) patients. 
Data collection rates varied according to the individual 
assays and the amount of tissue available. Notably, the 
success rate of sampling for β-catenin IHC did not differ 
between centers recruiting low (≤2; 77% success) and 
high (>7; 80%) patient numbers. Cases with available 
biological data from each assay were distributed randomly 
across the major disease demographics were thus 
considered representative of the whole cohort for further 
analysis (Supplementary Table 1).
Statistical analysis
EFS was deined as time from diagnosis to 
recurrence, progression or death during remission (of 
any reason). Patients not experiencing an event were 
censored at last follow-up. The database and biological 
data collection for this analysis was closed July 1st 2010. 
Kaplan–Meier curves, log-rank tests and unadjusted Cox 
proportional hazards models were used to test univariate 
EFS markers. Adjusted Cox proportional hazards 
models were used to test for independent disease-
risk markers. For univariate and multivariate survival 
analyses which included ‘time to radiotherapy’ (as a 
continuous variable), EFS times were landmarked to 
the commencement of radiotherapy. Risk stratiication 
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models for standard-risk medulloblastoma were developed 
in the cohort of M0/R0 patients with data available for 
all prognostic parameters (n = 118). This cohort was 
demographically representative of the entire standard-risk 
cohort within HIT-SIOP-PNET4 (n = 286; Supplementary 
Table 2). Associations between clinico-pathologic and/or 
molecular variables were examined using Fisher’s exact 
or Χ2 tests, as appropriate. P-values were corrected for 
multiplicity using the Bonferroni method where indicated. 
Analysis was performed using SPSS (SPSS, Chicago, 
U.S.A.) and R [40] software. Data proportions presented 
in Tables and Figures are based on patients with available 
data and may not add to 100% due to rounding.
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